Inke Acquires Pharmanoid from Gentec Pharmaceutical Group

December 18, 2025

Inke, supported by Keensight Capital, has acquired Pharmanoid, a specialized HPAPI manufacturing site focused on ophthalmic active pharmaceutical ingredients, from Gentec Pharmaceutical Group. The acquisition expands Inke's HPAPI capabilities beyond respiratory APIs and strengthens its position in ophthalmology and other therapeutic areas.

Buyers
Inke, Keensight Capital
Targets
Pharmanoid
Sellers
Gentec Pharmaceutical Group
Platforms
Inke
Industry
Pharmaceuticals
Location
Catalonia, Spain
Transaction Type
Addon

Explore More

Related articles

Build a buyer list for your deal

Find active buyers from recent acquisition patterns and move straight into outreach.

Find buyers like these →